Quoin Pharmaceuticals Ltd Financials
This page shows Quoin Pharmaceuticals Ltd (QNRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Quoin Pharmaceuticals Ltd passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Quoin Pharmaceuticals Ltd generates $0.88 in operating cash flow (-$7.9M OCF vs -$9.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Quoin Pharmaceuticals Ltd reported -$9.0M in net income in fiscal year 2024. This represents a decrease of 3.2% from the prior year.
Quoin Pharmaceuticals Ltd held $3.6M in cash against $0 in long-term debt as of fiscal year 2024.
Quoin Pharmaceuticals Ltd had 9M shares outstanding in fiscal year 2024. This represents an increase of 806.4% from the prior year.
Quoin Pharmaceuticals Ltd invested $3.6M in research and development in fiscal year 2024. This represents an increase of 8.9% from the prior year.
QNRX Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q2'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.3M+111.3% | $1.1M | N/A | $759K | N/A | $746K | N/A | $260K |
| SG&A Expenses | $1.7M+20.0% | $1.4M | N/A | $1.4M | N/A | $1.6M | N/A | $1.0M |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $203K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$3.9M-68.0% | -$2.3M | N/A | -$1.9M | N/A | -$3.0M | N/A | -$1.4M |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
QNRX Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q2'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.4M-59.1% | $15.7M+29.1% | $12.2M-19.2% | $15.1M+4.2% | $14.5M-12.0% | $16.4M+75.7% | $9.4M | N/A |
| Current Assets | $6.0M-59.7% | $14.9M+32.3% | $11.3M-20.2% | $14.1M+5.8% | $13.4M-14.6% | $15.7M+91.0% | $8.2M | N/A |
| Cash & Equivalents | $1.8M-49.5% | $3.6M+50.9% | $2.4M-24.1% | $3.2M+10.6% | $2.9M-45.5% | $5.2M-29.8% | $7.5M+1046.3% | $653K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $7.6M+17.4% | $6.5M0.0% | $6.5M-15.0% | $7.7M+8.5% | $7.1M-3.0% | $7.3M-16.4% | $8.7M | N/A |
| Current Liabilities | $5.8M+37.9% | $4.2M+16.7% | $3.6M-21.8% | $4.6M+29.8% | $3.5M-1.9% | $3.6M-21.4% | $4.6M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$1.2M-113.2% | $9.2M+62.5% | $5.7M-23.6% | $7.4M+0.1% | $7.4M-19.2% | $9.2M+1295.3% | $657K+104.0% | -$16.3M |
| Retained Earnings | -$66.6M-20.8% | -$55.2M-19.4% | -$46.2M-4.6% | -$44.2M-17.7% | -$37.5M-5.6% | -$35.5M-26.5% | -$28.1M+28.9% | -$39.5M |
QNRX Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q2'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.2M+0.5% | -$2.2M+30.6% | -$3.2M-143.9% | -$1.3M+32.0% | -$1.9M+15.3% | -$2.3M+27.9% | -$3.2M-250.3% | -$908K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $2.5M+179.8% | -$3.2M-220.2% | $2.6M+321946.3% | $821 | $0+100.0% | -$9.9M-3859.6% | -$250K-132.6% | -$108K |
| Financing Cash Flow | -$150K-102.5% | $5.9M+3343.1% | -$183K+33.6% | -$275K+38.5% | -$447K-103.0% | $14.8M+43.8% | $10.3M+19540.6% | -$53K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
QNRX Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q2'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -61.5%-40.8pp | -20.6% | N/A | -12.8% | N/A | -18.4% | N/A | N/A |
| Current Ratio | 1.04-2.5 | 3.57+0.4 | 3.15+0.1 | 3.09-0.7 | 3.79-0.6 | 4.35+2.6 | 1.79 | N/A |
| Debt-to-Equity | -6.29-7.0 | 0.71-0.4 | 1.15+0.1 | 1.03+0.1 | 0.95+0.2 | 0.79-12.4 | 13.24 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Quoin Pharmaceuticals Ltd profitable?
No, Quoin Pharmaceuticals Ltd (QNRX) reported a net income of -$9.0M in fiscal year 2024.
What is Quoin Pharmaceuticals Ltd's operating cash flow?
Quoin Pharmaceuticals Ltd (QNRX) generated -$7.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Quoin Pharmaceuticals Ltd's total assets?
Quoin Pharmaceuticals Ltd (QNRX) had $15.7M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Quoin Pharmaceuticals Ltd spend on research and development?
Quoin Pharmaceuticals Ltd (QNRX) invested $3.6M in research and development during fiscal year 2024.
How many shares does Quoin Pharmaceuticals Ltd have outstanding?
Quoin Pharmaceuticals Ltd (QNRX) had 9M shares outstanding as of fiscal year 2024.
What is Quoin Pharmaceuticals Ltd's current ratio?
Quoin Pharmaceuticals Ltd (QNRX) had a current ratio of 3.57 as of fiscal year 2024, which is generally considered healthy.
What is Quoin Pharmaceuticals Ltd's debt-to-equity ratio?
Quoin Pharmaceuticals Ltd (QNRX) had a debt-to-equity ratio of 0.71 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Quoin Pharmaceuticals Ltd's return on assets (ROA)?
Quoin Pharmaceuticals Ltd (QNRX) had a return on assets of -57.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Quoin Pharmaceuticals Ltd's cash runway?
Based on fiscal year 2024 data, Quoin Pharmaceuticals Ltd (QNRX) had $3.6M in cash against an annual operating cash burn of $7.9M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Quoin Pharmaceuticals Ltd's Piotroski F-Score?
Quoin Pharmaceuticals Ltd (QNRX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Quoin Pharmaceuticals Ltd's earnings high quality?
Quoin Pharmaceuticals Ltd (QNRX) has an earnings quality ratio of 0.88x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.